Stroke risk after abrupt internal carotid artery sacrifice: accuracy of preoperative assessment with balloon test occlusion and stable xenon-enhanced CT.

PURPOSE: To evaluate stable xenon-enhanced CT cerebral blood flow with balloon test occlusion as a predictor of stroke risk in internal carotid artery sacrifice. METHODS: Abrupt internal carotid artery occlusion was performed by surgical or endovascular means below the origin of the ophthalmic artery in 31 normotensive patients who were assessed preoperatively by a 15-minute clinical balloon test occlusion followed by an internal carotid artery-occluded xenon CT cerebral blood flow study. RESULTS: One patient, who passed the clinical test occlusion but exhibited regions of cerebral blood flow less than 30 mL/100 g per minute on the occlusion xenon CT cerebral blood flow study went on to have a fatal stroke corresponding exactly to the region of reduced blood flow. Thirty patients passed both components of the preoperative stroke-risk assessment. Neuroimaging demonstrated possible flow-related infarctions, which subsequently developed in three patients. Two patients were asymptomatic, and one patient was left with a mild residual hemiparesis. CONCLUSIONS: Our protocol provided a statistically significant reduction in subsequent infarction rate and infarction-related death rate when compared with a control group of normotensive abrupt internal carotid artery occlusion patients who did not undergo any preoperative stroke-risk assessment (reported in the literature). The estimated false-negative rate for our preoperative assessment protocol ranged from 3.3% to 10% depending on the assessment of the cause of the three potentially flow-related infarctions. Although life-threatening major vascular territory infarctions have been avoided, our protocol is less sensitive to changes predicting smaller, often minimally symptomatic, vascular border zone infarctions and does not predict postoperative thromboembolic strokes.

Cranial nerve length predicts the risk of delayed facial and trigeminal neuropathies after acoustic tumor stereotactic radiosurgery.

PURPOSE: To test the hypothesis that length of cranial nerve irradiated is a major factor predicting the risk of cranial nerve injury following radiosurgery and to identify any other significant related treatment factors. METHODS AND MATERIALS: Ninety-two patients (93 acoustic tumors) were treated with a 201 source Cobalt-60 gamma unit from 1987 to 1990 and prospectively followed. The range of minimum tumor dose was 12-20 Gy and maximum dose 24-50 Gy. Univariate and multivariate analyses were used to evaluate any correlations between tumor measurements and treatment factors, with the development of trigeminal and facial neuropathies following radiosurgery. RESULTS: The risks of trigeminal and facial neuropathy following radiosurgery were associated with the pon-petrous distance and mid porous transverse tumor diameters respectively (anatomically related to the irradiated length of cranial nerves V and VII respectively) in both univariate (p = .002 for V and p = .026 for VII) and multivariate (p = .004 for V and p = .055 for VII) analyses. Tumor volume, other tumor measurements, maximum dose, minimum tumor dose, and tumor dose inhomogeneity were not significantly related to either trigeminal or facial neuropathy in univariate and multivariate analyses. CONCLUSION: Within a minimum tumor dose range of 12-20 Gy, the incidence of delayed trigeminal or facial neuropathy depended more on the estimated length of nerve irradiated than the tumor dose or tumor volume. In the future, the risk of delayed facial or trigeminal cranial neuropathy may be reduced significantly by performing radiosurgery when the tumor still has both a small mid-porous transverse diameter and a small pons-petrous distance.

Neuroimaging of acoustic nerve sheath tumors after stereotaxic radiosurgery.

Using a strict method for measuring tumor size, we evaluated tumor response to radiosurgery in 88 patients with 89 acoustic tumors treated over 3 years with a 201-source cobalt-60 gamma unit. Overall, tumor size was unchanged in 73% of patients and increased in 4%. In 22% of patients, tumor diameter decreased an average of 4.9 mm 3-33 months after treatment. Tumor shrinkage occurred in 36% of 50 patients who were followed for at least 1 year after treatment. Loss of tumor contrast enhancement was seen in 79% of patients 1-18 months after treatment. Delayed communicating hydrocephalus developed in four patients. In eight patients, increased signal on T2-weighted MR images developed in the adjacent cerebellar peduncle (n = 5) or the peduncle and dorsolateral pons (n = 3) 5-15 months after treatment. T1-weighted MR imaging and CT were insensitive to these adjacent brain changes. Stereotaxic radiosurgery is an important alternative treatment for selected patients with acoustic tumors. There is no mortality or major perioperative morbidity, hospitalization time and costs are smaller than for microsurgery, patient employment or functional level is maintained, and hearing preservation and facial neuropathy rates are comparable to those in published microsurgical series. Although the rate of occurrence of trigeminal neuropathy is greater than those reported in published microsurgical series, the majority of cases are mild, transient, and nondebilitating. MR imaging before and after radiosurgery is the most sensitive imaging tool to evaluate tumor response, the presence of adjacent parenchymal signal changes, and ventricular size. With a mean follow-up time of 14.6 months, the rate of complications detected by neuroimaging is low and the tumor control rate is 96%.